Patents by Inventor Damien Marsic
Damien Marsic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12188037Abstract: Compositions and methods for producing modified AAV Cap genes and combinatorial libraries of chimeric AAV vectors and virions in an AAV serotype 3 background. Selecting for modified AAV3 virions displaying cell- or tissue-specific tropisms differing from WT AAV3. Using the synthetic combinatorial AAV3 capsid libraries for introducing into a selected target host cells one or more nucleic acid molecules useful in diagnostic and/or therapeutic gene-therapy regimens.Type: GrantFiled: October 21, 2016Date of Patent: January 7, 2025Assignee: University of Florida Research Foundation, IncorporatedInventors: Sergei Zolotukhin, Damien Marsic
-
Publication number: 20230340526Abstract: Disclosed herein are recombinant AAV variant (e.g., variant serotype 3B (AAV3B)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce hepatic cells. Viral particles containing these capsid variants are capable of evading neutralization by the host humoral immune response. The recombinant AAV3B variant proteins and viral particles disclosed herein were identified from a variant AAV3B capsid library that was engineered by making substitutions in only the variable regions of the capsid. Some embodiments of the AAV3B capsid variants disclosed herein comprise the AAV3B-DE5 variant, which contains 24 mutations relative to wild-type. Compositions of these variant AAV particles are provided that are useful for transducing and delivering therapeutic transgenes to cells, such as liver cells, and thus treat diseases and disorders pertaining to these cells.Type: ApplicationFiled: November 24, 2020Publication date: October 26, 2023Applicant: University of Florida Research Foundation, IncorporatedInventors: Sergei Zolotukhin, Roland Wilfried Herzog, Damien Marsic, Moanaro Biswas
-
Patent number: 11767346Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (for example, variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.Type: GrantFiled: March 8, 2022Date of Patent: September 26, 2023Assignees: University of Florida Research Foundation, Incorporated, The UAB Research FoundationInventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Paul D. Gamlin
-
Publication number: 20230049066Abstract: Disclosed herein are recombinant AAV variant (e.g., variant serotype 3B (AAV3B)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce hepatic cells. Viral particles containing these capsid variants are capable of evading neutralization by the host humoral immune response. The recombinant AAV3B variant proteins and viral particles disclosed herein were identified from a variant AAV3B capsid library that was engineered by making substitutions in only the variable regions of the capsid. Some embodiments of the AAV3B capsid variants disclosed herein comprise the AAV3B-G3 variant and the AAV3B-E12 variant. Compositions of these variant AAV particles are provided that are useful for transducing and delivering therapeutic transgenes to cells, such as liver cells, and thus treat diseases and disorders pertaining to these cells.Type: ApplicationFiled: November 24, 2020Publication date: February 16, 2023Applicants: University of Florida Research Foundation, Incorporated, University of Massachusetts One Beacon StreetInventors: Sergei Zolotukhin, Damien Marsic, Christian Murller
-
Publication number: 20220267383Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.Type: ApplicationFiled: March 8, 2022Publication date: August 25, 2022Applicants: University of Florida Research Foundation, Incorporated, The UAB Research FoundationInventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Paul D. Gamlin
-
Patent number: 11332502Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.Type: GrantFiled: September 1, 2020Date of Patent: May 17, 2022Assignees: University of Florida Research Foundation, Incorporated, The UAB Research FoundationInventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Nicholas Muzyczka, Hector Ruben Mendez-Gomez, Paul D. Gamlin
-
Patent number: 11091777Abstract: Disclosed are compositions and methods for producing modified adeno-associated virus (AAV) cap genes and combinatorial libraries of chimeric AAV vectors and virions; selecting for virions displaying cell-specific tropisms; and, in certain embodiments, producing helper vectors containing one or more modified AAV cap genes. The synthetic combinatorial AAV capsid libraries of the invention are useful in introducing into selected target host cells one or more nucleic acid molecules. The viral vectors and genetic constructs disclosed herein are also useful in a variety of diagnostic and/or therapeutic gene-therapy regimens.Type: GrantFiled: December 3, 2018Date of Patent: August 17, 2021Assignee: University of Florida Research Foundation, IncorporatedInventors: Damien Marsic, Sergei Zolotukhin, Mavis Agbandje-McKenna
-
Publication number: 20210061863Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.Type: ApplicationFiled: September 1, 2020Publication date: March 4, 2021Applicants: University of Florida Research Foundation, Incorporated, The UAB Research FoundationInventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Nicholas Muzyczka, Hector Ruben Mendez-Gomez, Paul E. Gamlin
-
Patent number: 10793606Abstract: Adeno associated viral (AAV) particles are emerging as useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.Type: GrantFiled: August 21, 2019Date of Patent: October 6, 2020Assignees: University of Florida Research Foundation, Incorporated, The UAB Research FoundationInventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Paul D. Gamlin
-
Publication number: 20200181644Abstract: Compositions and methods for producing modified AAV Cap genes and combinatorial libraries of chimeric AAV vectors and virions in an AAV serotype 3 background. Selecting for modified AAV3 virions displaying cell- or tissue-specific tropisms differing from WT AAV3. Using the synthetic combinatorial AAV3 capsid libraries for introducing into a selected target host cells one or more nucleic acid molecules useful in diagnostic and/or therapeutic gene-therapy regimens.Type: ApplicationFiled: October 21, 2016Publication date: June 11, 2020Applicant: University of Florida Research Foundation, IncorporatedInventors: Sergei Zolotukhin, Damien Marsic
-
Publication number: 20200002386Abstract: Adeno associated viral (AAV) particles are emerging as useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.Type: ApplicationFiled: August 21, 2019Publication date: January 2, 2020Applicants: University of Florida Research Foundation, Incorporated, The UAB Research FoundationInventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Nicholas Muzyczka, Hector Ruben Mendez-Gomez, Paul D. Gamlin
-
Publication number: 20190249195Abstract: Disclosed are compositions and methods for producing modified adeno-associated virus (AAV) cap genes and combinatorial libraries of chimeric AAV vectors and virions; selecting for virions displaying cell-specific tropisms; and, in certain embodiments, producing helper vectors containing one or more modified AAV cap genes. The synthetic combinatorial AAV capsid libraries of the invention are useful in introducing into selected target host cells one or more nucleic acid molecules. The viral vectors and genetic constructs disclosed herein are also useful in a variety of diagnostic and/or therapeutic gene-therapy regimens.Type: ApplicationFiled: December 3, 2018Publication date: August 15, 2019Applicant: University of Florida Research Foundation, IncorporatedInventors: Damien Marsic, Sergei Zolotukhin, Mavis Agbandje-McKenna
-
Publication number: 20160369298Abstract: Disclosed are compositions and methods for producing modified adeno-associated virus (AAV) cap genes and combinatorial libraries of chimeric AAV vectors and virions; selecting for virions displaying cell-specific tropisms; and, in certain embodiments, producing helper vectors containing one or more modified AAV cap genes. The synthetic combinatorial AAV capsid libraries of the invention are useful in introducing into selected target host cells one or more nucleic acid molecules. The viral vectors and genetic constructs disclosed herein are also useful in a variety of diagnostic and/or therapeutic gene-therapy regimens.Type: ApplicationFiled: September 26, 2014Publication date: December 22, 2016Inventors: Damien Marsic, Sergei Zolotukhin, Mavis Agbandje-McKenna